Definium Therapeutics, Inc. (DFTX) stock
DFTXNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
$32.08−0.92 (-2.79%)
Close on Nov 13, 2026Market cap $4.31BP/E –Yield –
Definium Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Definium Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$191.36M. For fiscal 2025 it was -$131.56M. The highest annual figure on record is -$23.60M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$131.56M | – |
| FY2024 | Dec 31, 2024 | -$79.13M | – |
| FY2023 | Dec 31, 2023 | -$64.37M | – |
| FY2022 | Dec 31, 2022 | -$50.14M | – |
| FY2021 | Dec 31, 2021 | -$45.82M | – |
| FY2020 | Dec 31, 2020 | -$23.60M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$52.98M | – |
| Q2 FY2026 | Jun 30, 2026 | -$52.78M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.63M | – |
| Q4 FY2025 | Dec 31, 2025 | -$42.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.42M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.63M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.85M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.33M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.87M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.78M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.04M | – |
See a number that looks wrong?